Tagrisso Approved in Japan for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

09:50 EDT 21 Aug 2018 | Pharmaceutical Processing

News
The FDA has approved Tagrisso for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Contributed Author: 
AstraZeneca
Topics: 
Oncology

More From BioPortfolio on "Tagrisso Approved in Japan for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer"